AI-generated analysis. Always verify with the original filing.
Enveric Biosciences reported a net loss of $4.0 million for Q4 2025 and provided a corporate update highlighting positive preclinical results for lead candidate EB-003 and intellectual property developments. The company is preparing an IND submission for EB-003 and raised $12.2 million in gross proceeds during fiscal year 2025.
Event Type
Disclosure
Mandatory
Variant
8-K
shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject t
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated March 27, 2026 (furnished pursuant to Item 2.02) 104 Cover
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $4.00 | |
| Basic and Diluted Loss Per Share | $6.12 |